程序性死亡受体1抑制剂卡瑞利珠单抗治疗老年性晚期肺鳞癌1例并文献复习

A case report and literature review of programmed death receptor 1 inhibitor camrelizumab in the treatment of senile advanced lung squamous cell carcinoma

肺癌是目前全世界发病率及病死率均居前列的恶性肿瘤。近年来,基于驱动基因突变阳性的分子靶向精准治疗彻底改变了晚期肺癌患者的治疗模式。但针对驱动基因突变阴性的晚期肺癌患者的治疗效果仍不理想,免疫治疗尤其是以程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)和细胞毒T淋巴细胞相关抗原4(CTLA-4)为靶点的免疫抑制剂的出现彻底改变了晚期驱动基因阴性患者的治疗格局,提高了晚期肺癌患者的总生存期(OS)和生活质量。本文总结一例PD-1抑制剂卡瑞利珠单抗治疗晚期肺鳞老年患者的疗效及安全性,为临床提供参考。

At present,lung cancer is in the forefront of all malignant tumors with the highest morbidity and mortality in the world.In recent years,molecular targeted precise therapy based on positive driving gene mutation has completely changed the treatment mode of patients with advanced lung cancer.However,the therapeutic efficacy on patients with advanced lung cancer with negative driving gene mutation is still unsatisfactory.Immunotherapy,especially the emergence of immunosuppressants targeting programmed death receptor 1(PD-1)/programmed death ligand-1(PD-L1)and cytotoxic T lymphocyte associated antigen-4(CTLA-4),has completely changed the treatment pattern of patients with late negative driving gene,and improved the overall survival time(OS)and quality of life of patients with advanced lung cancer.The efficacy and safety of 1 case of PD-1 inhibitor camrelizumab in the treatment of elderly patients with advanced pulmonary scales are summarized in this paper,so as to provide reference for clinical application.